Drug | Tablet

Type 2 diabetes mellitus: to improve glycaemic control as an add-on to diet and exercise in adults when treatment with both dapagliflozin and metformin is appropriate.

Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys and also promotes mild diuresis. Metformin reduces hepatic glucose production and improves insulin sensitivity, decreasing intestinal glucose absorption and improving peripheral glucose uptake.

Oral tablet. Take exactly as prescribed, usually once daily (or as directed) with food to reduce stomach upset; swallow whole with water. Maintain adequate hydration; follow diet/exercise advice and monitor blood glucose as advised.

Nausea,diarrhoea,abdominal pain,loss of appetite,metallic taste,genital fungal infection (thrush),urinary tract infection,increased urination,thirst,dizziness,low blood sugar (especially with insulin/sulfonylureas)

Schedule H: use under medical supervision. Metformin may rarely cause lactic acidosis—risk increases with severe kidney disease, dehydration, sepsis, excessive alcohol use, liver disease, or hypoxia; stop and seek care if rapid breathing, severe weakness, abdominal pain, or unusual sleepiness occurs. Dapagliflozin may cause genital/urinary infections, volume depletion/low BP, and (rare) ketoacidosis even with near-normal sugars—seek urgent care for nausea/vomiting, abdominal pain, rapid breathing, confusion. Assess kidney function before and during therapy; not recommended in severe renal impairment; temporary interruption may be needed during acute illness, prolonged fasting, major surgery, or iodinated contrast procedures as per clinician advice. Monitor for hypoglycaemia when used with insulin or sulfonylureas.

Insulin and sulfonylureas (increased hypoglycaemia risk),diuretics (increased dehydration/low BP risk),ACE inhibitors/ARBs/NSAIDs (may affect kidney function especially with dehydration),iodinated contrast media (increased lactic acidosis risk with metformin—temporary withholding may be required),carbonic anhydrase inhibitors e.g. topiramate/acetazolamide (increased metabolic acidosis risk),cimetidine (may increase metformin levels),alcohol (increases lactic acidosis risk),rifampicin/phenytoin (may alter glycaemic control)

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Xigduo XR 10/500 Tablet,Glyxambi M 10/500 Tablet (where available),Dapamet 10/500 Tablet,Dapaflo-M 10/500 Tablet,Dapanorm M 10/500 Tablet